Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab monthly versus alternative quarterly-maintenance dosing in neovascular age-related macular degeneration
2005-003517-33Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2005
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab in age-related macular degeneration (AMD) and Subretinal neovascularization (3 arms), sponsored by Novartis. Primary endpoint: Mean change in best-corrected visual acuity from baseline to Month 12. Started Oct 2005; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2005-003517-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003517-33.